PATENT

Attorney Docket:

7640-X04-017

MAR 0 9 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Appln. of:

Israel VLODAVSKY et al

Group Art Unit:

1614

Appln. No.:

10/789,428

Filed:

February 27, 2004

For:

EOSINOPHIL MAJOR BASIC PROTEIN AS A NATURAL

HEPARANASE-INHIBITING PROTEIN, COMPOSITIONS, METHODS

AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Dear Sir:

Submitted herewith are:

- (1) Form: PTO/SB/08a and PTO/SB/08b; and
- (2) Copies of the publications cited in said PTO/SB/08a and PTO/SB/08b.

It is requested that an initialed copy of the form PTO/SB/08a be returned to indicate that the publications listed therein have been considered and made of record.

A fee of \$180 is enclosed for filing an Information Disclosure Statement at this stage of prosecution. Enclosed is a Form PTO-2028 (Credit Card Form). If any deficiencies in fees are due, please charge Deposit Account 500601 for such sum (Docket No. 7640-X04-017).

08420402 E0200000 XXXXXXXX E00040180

06 F381005

203.00 02

Respectfully submitted,

Martin Fleit, Reg. #16,900

୦୦ :୯₃ Martin Fleit

FLEIT KAIN GIBBONS GUTMAN BONGINI & BIANCO, P.L.

601 Brickell Key Drive Suite 404

Miami, Florida 33131

Tel: 305-416-4490; Fax: 305-416-4489

e-mail: MFleit@FocusOnIP.com



Attorney Docket No:

7640-X04-017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:

Israel VLODAVSKY, Gerald J. GLEICH and Francesca

LEVI-SCHAFFER

Serial No.:

10/789,428

Group Art Unit: 1614

Filed:

February 27, 2004

Examiner:

Title:

EOSINOPHIL MAJOR BASIC PROTEIN AS A NATURAL HEPARANASE-INHIBITING PROTEIN, COMPOSITIONS,

METHODS AND USES TEHEOF

CERTIFICATE OF EXPRESS MAILING

PATENTS

EXPRESS "Express Mail" Mailing Label number EV 674788887 US Date of March 9, 2005

I hereby certify that the attached paper(s) or fee(s) is/are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

(Signature of person mailing paper or fee)

ESTEFANIA BELAUNDE

(Typed or printed name of person mailing paper or fee)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

abstitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/789,428				
Filing Date	February 27, 2004				
First Named Inventor	Israel VLODAVSKY				
Art Unit	1614				
Examiner Name					
Attorney Docket Number	7640-X04-017				

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (J known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		US-						
	•	US-						
		US-						
		US-		· · · · · · · · · · · · · · · · · · ·				
		US-						
	· - -	US-						
		US-						
		US-						
		US-						
		ŪS-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [©]			
		WO 02/060374 A2	08-08-2002	Insight Strategy & Marketing Ltd					

Examiner		 Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov.or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/789,428 INFORMATION DISCLOSURE Filing Date February 27, 2004 STATEMENT BY APPLICANT First Named Inventor Israel VLODAVSKY Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 2 7640-X04-017

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials* Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	1	Bernard, D. et al., J. Invest. Dermatol. 117:1266-73 (2001)					
	2	Carlson, M.G. et al., J, Iminunol. 134:1875-9 (1985)					
	3	Chekhonin V.P. et al., Vopr, Med. Khim. 46:54963 (2000) (abstract only)					
	4	Dempsey, L.A. et al., Trends Biochem. Sci. 25:349-51 (2000)					
	5	Fairbanks, M.B. et al., J. Biol. Chem. 274:29587-29590 (1999)					
	6	Friedmann, Y. et al., Am. J. Pathol. 157:1167-1175 (2000)					
	7	Gleich, G.J., Allergy Clin. Immunol. 105:651-663 (2000)					
•	8	Gleich, G.J. J. et al., Clin. Invest 57:633-40 (1976)					
***************************************	9	Goldshmidt, O. et al., Exp. Cell Res. 281:50-62 (2002)					
	10	Goldshmidt, O. et al., J. Biol. Chem. 276:29178-87 (2001)					

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Substitute	Substitute for form 1449B/PTO			Complete if Known		
					Application Number	10/789,428	
INFORMATION DISCLOSURE					Filing Date	February 27, 2004	
	STATEMENT BY APPLICANT			ICANT	First Named Inventor	Israel VLODAVSKY	
					Art Unit	1614	
(Use as many sheets as necessary)					Examiner Name		
abla	Sheet	3	of	7	Attorney Docket Number	7640-X04-017	

NON PATENT LITERATURE DOCUMENTS								
Examiner Cit No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	11	Goldshmidt, O. et al., Proc. Natl. Acad. Sci. USA 99:10031-6 (2002)						
	12	Gong et al. J. Biol. Chem. 278:35152-35158 (2003)						
	13	Hallsworth, M.P. et al., Am. J. Respir. Cell Mol. Biol. 19:910-9 (1998)						
	14	Hoenstein R. et al., Cell. Immunol. 210:116-24 (2001)						
	15	Hulett, M.D. et al., Nat. Med. 5:803-809 (1999)						
	16	Kawase, Y. J. Antibiotics 49:61-64 (1995)						
	17	Kuhry, J.G. et al., Agents Actions 16:109-12 (1985)						
•	18	Levi-Schaffer, F. et al., Proc. Natl. Acad. Sci. USA 96:9660-5 (1999)						
•	19	Lider, O. J. et al., Clin. Invest. 83:752-756 (1989)						
	20	Mallorqui-Fernandez, G. et al., J, Mol. Biol. 300:1297-307 (2000)						

1					1
	Examiner		Date		
۱	Signature		Considered		}

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Substitute (for form 1449B/PTO	-	-	Complete if Known		
	INFORMATION DISCLOSURE				Application Number	10/789,428	
					Filing Date	February 27, 2004	
STATEMENT BY APPLICANT			ICANT	First Named Inventor	Israel VLODAVSKY		
					Art Unit	1614	
(Use as many sheets as necessary)					Examiner Name		
	Sheet	4	of	7	Attorney Docket Number	7640-X04-017	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bod magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²				
	21	Matzner, Y. et al., J. Clin. Invest. 76:1306-13 (1985)				
	22	Mollinedo, F. et al., Biochem. J. 327:917-923 (1997)				
	23 Nadav, L. et al., J. Cell Sci. 115(10):2179-87 (2002)					
	24 Nagler, A. et al., Arteriosclerosis, Thrombosis & Vascular Biol. 17:194-202 (1997)					
	25	Nakajima, M. et al., J. Cell. Biochem. 36:157-163 (1988)				
	26	Nakajima, M. et al., J. Biol. Chem, 266:9661-9666 (1991)				
	27	Nishimura, Y. et. al., O. Antibiot, 47:101407 (1994)				
	28	O'Donnell, M.C. et al., J. Exp. Med. 157:1981-91 (1983)				
	29	Parish, C.R. et al., Biochim. Biophys. Acta. 1471:M99-M108 (2001)				
	30	Parish, C.R, et al,, Cancer Res. 59:3433-3441 (1999)				

1	ſ		1
	Examiner	Date	
	Signature	Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/789,428	
INFC	RMATION DI	SCLC	SURE	Filing Date	February 27, 2004	
STA	TEMENT BY A	APPLI	CANT	First Named Inventor	Israel VLODAVSKY	
				Art Unit	1614	
	(Use as many sheets as	necessary)	Examiner Name		
Sheet	5	of	7	Attorney Docket Number	7640-X04-017	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	31	Parish, C.R. et al., Int. J. Cancer 40:511-518 (1987)				
	32	Pikas, D.S, et al., J. Biol. Chem. 273:18770-18777 (1998)				
	33	Samoszuk M. Histol Histopathol. 12:807-12 (1997) (Abstract only)				
	34	Shteper, P.J. et al., Oncogene 22:7737-7749 (2003)				
	35	Simon H-U. et al., J. Immunol. 165:4069-75 (2000)				
	36	Slifman, N. R. et al., J. Immunol. 137:2913-291.7 (1986)				
	37	Solomon, A. et al., Invest. Ophthalmol. Vis. Sci. 41:1038-44 (2000)				
	38	Stetler-Stevenson, W.G. and Yu, A.E. Semin. Cancer Biol. 11:143-52 (2001)				
	39	Temkin, V. et al., J. Immunol. 169:2662-9 (2002)				
	40	Temkin, V. et al., Cytokine 24: 74-80 (2003)				

Examiner	Date	
Signature	Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute t	for form 1449B/PTO			Complete if Known			
				Application Number	10/789,428		
	RMATION DI			Filing Date	February 27, 2004		
STA	STATEMENT BY APPLICANT			First Named Inventor	Israel VLODAVSKY		
				Art Unit	1614		
(Use as many sheets as necessary)				Examiner Name			
Sheet	6	of	7	Attorney Docket Number	7640-X04-017		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	41	Thomas, L.L. et al., Immunol. Lett. 78:175-81 (2001)				
	42	Vlodavsky, I, et al., Cancer Res. 43:2704-2711 (1983)				
	43	Vlodavsky, I. et al., Isr, J, Med. 24:464-470 (1988)				
	44	Vlodavsky, I. et al., Trends Biochem. Sci. 16:268-71. (1991)				
	45	Vlodavsky, I. et al., invasion & Metastasis 12:112-127 (1992)				
	46	Vlodavsky, I. et al., Invasion Metastasis 14:290-302 (1994)				
	47	Vlodavsky, I. et al., Tumor Angiogenesis. Eds. C. E. Lewis, R. Bicknell & N. Ferrara. Oxford Uni				
	48	Vlodaysky, I. et al., Nat. Med. 5:793-802 (1999a)				
	49	Vlodaysky, I. et at., Current Protocols in Cell Biology. Vol 1. New York, NY: John Wiley & Sons				
	50	Vlodavsky, I. and Friedmann, J. Clin. Invest. 108:341-7 (2001)				

1		1	
ı	Examiner	Date	
Į	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute	for form 1449B/PTO			Complete if Known			
				Application Number	10/789,428		
INFORMATION DISCLOSURE			SURE	Filing Date	February 27, 2004		
STA	TEMENT BY	APPL	ICANT	First Named Inventor	Israel VLODAVSKY		
				Art Unit	1614		
(Use as many sheets as necessary)			<i>(</i>)	Examiner Name			
Sheet	7	of	7	Attorney Docket Number	7640-X04-017		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.				
	51	White, R. et al., J. Immunol. Methods 44: 257-63 (1991) (Abstract only)			
	52	Zetser et al., Can. Res. 63:7733-7741 (2003)			
••••••••••••					
•••••••••••••••••••••••••••••••••••••••	••••••				
•••••••••••			••••••		
•••••••••••••••••••••••••••••••••••••••					
	•••••••••••••••••••••••••••••••••••••••				
•••••					
Examiner Signature		Date Considered			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.